Herbert Timothy P. 的 Form 4/A 修正申報
修正Inspire Medical Systems, Inc.（INSP），2024/4/3 申報
- 申報編號
- 0001104659-24-043288
- 申報時間
- 2024/4/3
- 交易日
- 2024/4/1
- 申報延遲
- 2 天
- 10b5-1 計畫
- 有勾選
- 原始申報日
- 2024/4/1
這份申報列了 9 筆非衍生性交易。公開市場賣出合計 $820.4 萬。交易後 2 天申報。
這份修正申報取代了 0001104659-24-043244（2024/4/3 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Herbert Timothy P.CIK 0001737136 | 董事、高階主管（執行長、總裁） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/4/1 | Common Stock | S賣出處分 | −9,388 | $203.33F1 | −$1,908,862.04 | 94,270 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −10,694 | $204.35F3 | −$2,185,318.9 | 83,576 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −11,645 | $205.27F4 | −$2,390,369.15 | 71,931 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −3,379 | $206.19F5 | −$696,716.01 | 68,552 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −1,420 | $207.25F6 | −$294,295 | 67,132 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −1,492 | $208.34F7 | −$310,843.28 | 65,640 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −1,310 | $209.46F8 | −$274,392.6 | 64,330 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −232 | $210.99F9 | −$48,949.68 | 64,098 | 間接 | |
| 2024/4/1 | Common Stock | S賣出處分 | −440 | $213.26F10 | −$93,834.4 | 63,658 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.785 to $203.78. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F2
Securities held by the Timothy P. Herbert 2018 Family Continuation Trust c/u the Timothy P. Herbert 2018 Grantor Retained Annuity Trust.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.785 to $204.78. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.80 to $205.78. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.80 to $206.775. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.825 to $207.79. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.885 to $208.80. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.19 to $209.76. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.935 to $211.06. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.03 to $213.99. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F11
Securities held by the TPH 2022 LLC.
- F12
Securities held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.
備註
This amendment is being filed to update the Form 4 filed on April 3, 2024 (the "Original Report") and reflect that the sales reported in the Original Report were made pursuant to a Rule 10b5-1 trading plan dated August 28, 2023.